Royal Bank Of Canada Raises Maricann Group (CNSX:MARI) Price Target to $16.00

Maricann Group (CNSX:MARI) had its price objective increased by research analysts at Royal Bank Of Canada from $6.00 to $16.00 in a report issued on Wednesday,BayStreet.CA reports.

A number of other research firms also recently commented on MARI. Beacon Securities boosted their price objective on Maricann Group from $12.00 to $15.00 and gave the stock a “buy” rating in a research note on Tuesday, August 26th. BMO Capital Markets lifted their price objective on shares of Maricann Group from $12.00 to $13.00 in a research report on Wednesday, August 27th. Finally, Raymond James Financial increased their target price on Maricann Group from $6.50 to $11.50 in a report on Thursday, August 21st. Three research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $13.30.

Maricann Group Price Performance

Maricann Group has a 1-year low of $0.87 and a 1-year high of $3.60.

Maricann Group Company Profile

Maricann Group Inc, formerly Danbel Industries Corporation, is a Canada-based integrated producer and distributor of marijuana for medical purposes. As one of approximately 43 companies with a federal license to cultivate cannabis and one of approximately 30 independent licensed producers with a federal license to process and distribute cannabis, the Company’s services a patient base with more than 8,000 registered patients.